The FDA recently issued an approval to Watson Laboratories for a generic version of a drug designed to control and prevent asthma symptoms in children, according to a press release.
Budesonide inhalation suspension, the generic version of Pulmicort Respules (AstraZeneca), is intended for children aged 12 months to 8 years and will be available in dose ampules of 0.25 mg/2mL and 0.5 mg/2mL.
The company, a subsidiary of Watson Pharmaceuticals, is currently in patent litigation with AstraZeneca, but anticipates launching the drug later this year pending the results of a motion for a preliminary injunction.